Day: May 21, 2021

Pompano Beach, FL, May 21, 2021 (GLOBE NEWSWIRE) — Brownie’s Marine Group, Inc. (OTCQB: BWMG), a leading developer, manufacturer and distributor of tankless dive equipment and high-pressure air and industrial compressors in the marine industry, today announced that they have entered into an exclusive distributor agreement with Chrysalis Trading CC DBA Bright Weights for the US and the Caribbean. Robert Carmichael, Chairman of Brownie’s Marine Group stated “We have been looking for the proper ballast systems that provides flexibility and is more unique than the traditional source of lead ballast available here in the US. Bright Weights provide us with additional items to service the dive community that are complementary to our Brownie’s line of tankless diving equipment. This exclusive distributorship will provide our customer base,...

WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today that members of its executive team, including Paul Friedman, M.D., Chief Executive Officer, Becky Taub, M.D., Chief Medical Officer and President of Research and Development, Remy Sukhija, Senior Vice President and Chief Commercial Officer and Alex Howarth, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 4:00 pm ET. The fireside chat will be webcast live and can be accessed in the Investor Relations section of the Madrigal website and will...

Earnings Release: Tuesday, May 25, 2021, Before Market Opens in New York Conference Call and Webcast: Tuesday, May 25, 2021, at 10:00 a.m. Eastern Time GLYFADA, Greece, May 21, 2021 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (“Seanergy” or the “Company”) (NASDAQ: SHIP) announced today that it will release its financial results for the first quarter ended March 31, 2020 before the market opens in New York on Tuesday, May 25, 2021. On the same day at 10:00 a.m. Eastern Time, the Company’s management will host a conference call to present the financial results. Webcast: Participants to the live webcast should register approximately 10 minutes prior to the start of the webcast, following the link http://seanergymaritime.irwebpage.com/2021-1Q.html. Conference Call Details: Participants have the option to dial into the call...

Westport, CT, May 21, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, Chairman, and CEO of BioSig Technologies, Inc. will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. The presentation will be available from 8am EST – 5pm EST  on the conference website Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com). The Company will also be available for one-on-one investor meetings. BioSig’s PURE EP(tm) System is an advanced signal acquisition and processing platform that sets a new standard in electrophysiology....

Unique combination of secure, federated instant messaging with Push-to-Talk radio comm, live video broadcasts, and emergency location sharing NEW YORK, NY, May 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — AdvanceTC Limited (NSX:A88, OTCQB:ATCLF), Satellite and mobile communication innovation leader, today announced the pre-launch testing of its StarzChat integrated and satellite-ready, voice chat platform, soon to be available free for iOS and Android, Windows, Linux, and macOS. Amidst a surge in downloads of alternative, encrypted, voice communication apps such as Signal and Telegram due to intensifying consumer and business security concerns, StarzChat is a groundbreaking communication platform combining secure, instant messaging with enhanced capabilities like Push-To-Talk radio communication, live video broadcasting,...

– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion when making national decisions about the early use of sotrovimab prior to EMA marketing authorization – – Discussions with global regulators regarding authorizations in additional countries continue to advance – LONDON and SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Vir Biotechnology, Inc. please note that the third subheadline of the release has been updated. The corrected release follows: GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LONGUEUIL, Quebec, May 21, 2021 (GLOBE NEWSWIRE) — Reunion Gold Corporation (“Reunion” or the “Company”) (TSX-V: RGD) is pleased to announce that it has closed its previously announced brokered private placement of 46,150,000 units (“Units”) at a price of $0.065 per Unit for gross proceeds of approximately C$3 million (the “Offering”). BMO Nesbitt Burns Inc. acted as lead agent and sole bookrunner on behalf of a syndicate of agents including Paradigm Capital Inc. and Dundee Goodman Merchant Partners (together, the “Agents”) under the Offering. Each Unit consisted of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“), with each Warrant exercisable...

Ownership rights of part of Ignitis Gamyba’s shares have been transferred to Ignitis Group AB “Ignitis grupė” (hereinafter – ‘Ignitis Group’ or ‘Company’) informs that following the decision of Vilnius District Court (hereinafter – the Court) of 30 April 2021, managers of securities accounts on 21 May have transferred money for the shares of AB “Ignitis Gamyba” (hereinafter – Ignitis Gamyba) held by part of the minority shareholders, in respect of whom the Court decision was made, in their personal securities accounts. Shareholders holding shares of Ignitis Gamyba in the issuer’s accounts will be transferred funds after submitting a request to SEB Bank (see below). On 21 May managers of securities accounts finished making records on the transfer of ownership rights for the part of shares of Ignitis Gamyba to Ignitis Group in respect...

AB “Ignitis grupė” (hereinafter – ‘Ignitis Group’ or ‘Company’) informs that following the decision of Vilnius District Court (hereinafter – the Court) of 30 April 2021, managers of securities accounts on 21 May have transferred money for the shares of AB “Ignitis Gamyba” (hereinafter – Ignitis Gamyba) held by part of the minority shareholders, in respect of whom the Court decision was made, in their personal securities accounts. Shareholders holding shares of Ignitis Gamyba in the issuer’s accounts will be transferred funds after submitting a request to SEB Bank (see below). On 21 May managers of securities accounts finished making records on the transfer of ownership rights for the part of shares of Ignitis Gamyba to Ignitis Group in respect of 10,989,527 units out of 11,113,442 units of shares, which were recognised as the property...

European Commission Decision Anticipated by July 2021 BUFFALO, N.Y., May 21, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall (Almirall, S.A., BME: ALM), has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the regulatory approval of Klisyri® (tirbanibulin), indicated for the topical treatment of actinic keratosis (AK) of the face or scalp. Tirbanibulin is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that represents a significant step forward in the treatment of AK due...